pioglitazone has been researched along with triiodothyronine in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (87.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Arifi, S; Bischoff, I; Chaikuad, A; Fürst, R; Gellrich, L; Goebel, T; Heering, J; Heitel, P; Kahnt, A; Kilu, W; Knapp, S; Merk, D; Paulke, A; Pogoda, W; Pollinger, J; Proschak, E; Schubert-Zsilavecz, M; Steinhilber, D; Wurglics, M | 1 |
Clerget-Froidevaux, MS; Decherf, S; Demeneix, B; Elgaaied, AB; Guissouma, H; Kouidhi, S; Seugnet, I | 1 |
1 review(s) available for pioglitazone and triiodothyronine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for pioglitazone and triiodothyronine
Article | Year |
---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
Topics: Amino Acid Sequence; Animals; Drug Evaluation, Preclinical; Male; Mice; Models, Molecular; PPAR gamma; Protein Conformation; Thyroxine | 2020 |
Peroxisome proliferator-activated receptor-gamma (PPARgamma) modulates hypothalamic Trh regulation in vivo.
Topics: Anilides; Animals; Animals, Newborn; Gene Expression Regulation; Gene Knockdown Techniques; Glucose Transporter Type 4; Hypothalamus; Injections, Intraventricular; Mice; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; Retinoid X Receptor alpha; Rosiglitazone; Thiazolidinediones; Thyroid Hormone Receptors beta; Thyrotropin-Releasing Hormone; Thyroxine; Transfection; Triiodothyronine | 2010 |